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ABSTRACT 
Laskowski inhibitors are receiving growing interest as engineering templates for designing reversible 
serine protease inhibitors. When optimizing binding interactions between the inhibitor and the target 
protease, many studies focus on the non-primed segment of the inhibitor’s binding loop (encompassing 
the contact β-strand). However, there are currently few methods for screening residues on the primed 
segment. In this study, we designed a versatile, synthetic inhibitor library (based on the cyclic peptide, 
sunflower trypsin inhibitor-1) for characterizing the binding specificity of various proteases at the P2 
prime (P2ʹ) position. Screening the library against thirteen different serine proteases, including trypsin, 
chymotrypsin, matriptase, plasmin, thrombin, four kallikrein-related peptidases, and several clotting 
factors, revealed that each displayed unique P2ʹ preferences. Further, using this information to modify the 
P2ʹ residue in several existing engineered inhibitors yielded new variants that showed considerably 
improved selectivity, reaching up to 7,000-fold selectivity over certain off-target proteases. Our study 
demonstrates the importance of the P2ʹ residue in Laskowski mechanism inhibition, and unveils a new 
method for screening P2ʹ substitutions that will benefit future inhibitor engineering studies. 
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INTRODUCTION 
Serine proteases are established therapeutic targets in a spectrum of medical conditions, including 
coagulation and cardiovascular diseases, metabolic disorders, inflammation, and infectious diseases1. 
Accordingly, the pharmaceutical industry has had a longstanding interest in developing therapeutic 
molecules that can modulate the activity of one or more proteases, with most attention directed towards 
protease inhibitors2. These drug discovery programs have provided a number of major successes, and an 
array of inhibitors targeting different proteases are currently used in the clinic2, including several new 
drugs on the market3. Traditionally, protease-based drug development has favored classical small 
molecule inhibitors as this approach often yields suitable lead compounds that have excellent 
pharmacokinetic properties. However, small molecule inhibitors typically have relatively few binding 
determinants, which can lead to challenges when translating drug leads from the laboratory to the clinic. 
First, the risk of limited selectivity is often higher for inhibitors that have fewer binding determinants. 
Off-target inhibition can cause negative side-effects in patients, and was regarded to be a contributing 
factor in the failure of first generation matrix-metalloproteinase inhibitors in clinical trials for preventing 
cancer metastasis4. Second, the emergence of drug resistance is more likely for inhibitors that have fewer 
binding determinants as only a small number of mutations are required for the target protein to evade drug 
binding. This is particularly relevant to therapies for rapidly evolving diseases, and is an ongoing concern 
for treating HIV5 and hepatitis C6 infections. To overcome these challenges, there is now growing interest 
in engineering naturally occurring peptide and small protein inhibitors that interact via larger binding 
surfaces and are capable of greater selectivity7. 
Laskowski (or standard mechanism) inhibitors8, 9 are a major class of serine protease inhibitors that fall 
between small molecule drugs and large protein biologics (in terms of molecular weight). These inhibitors 
are found in all forms of life, and operate by an intriguing mechanism that involves the protease cleaving 
then re-synthesizing the inhibitor’s reactive site bond10, 11. Despite sharing a common mode of action, 
Laskowski inhibitors show immense variety in sequence and structure, and segregate into at least 19 
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different families that display unique characteristics9. This is an advantage for drug development, as it 
provides a series of engineering templates that function in the same way but are structurally diverse, 
ranging in size from circular peptides (as small as 1.5 kDa) to larger protein domains (6-8 kDa). Indeed, 
only one structural feature is strictly conserved across all inhibitor families: the conformation of the 
inhibitor’s binding loop (termed the canonical loop)8, 12. This segment is pre-configured to match the 
geometry of the serine protease active site, and displays a variable sequence that is complementary to the 
substrate specificity profile of intended protease targets (spanning both primed (Pʹ) and non-primed (P) 
binding subsites: Schechter-Berger nomenclature13, Figure 1A). 
As with many protein-protein interactions, the sequence of the inhibitor’s binding loop has a major role in 
determining which proteases the inhibitor will be effective against. Therefore, engineering the sequence 
of the canonical loop is one of the main strategies for directing Laskowski inhibitors to new protease 
targets. New sequence combinations can be identified by several different methods, with those capable of 
screening both the non-primed and primed residues generally providing greater success. To date, the most 
widely used approach has been phage display, which is one of only a few methods where all residues of 
the canonical loop are accessible for optimization. Phage display was first applied to select potent 
inhibitors of neutrophil elastase14, then later used to develop the first engineered Laskowski inhibitor to 
reach the clinic, Ecallantide. This drug is a selective plasma kallikrein inhibitor based on the first Kunitz 
domain of tissue factor pathway inhibitor15 and is used to relieve inflammation in hereditary 
angioedema16.  
Alternatively, the template inhibitor can be engineered by rational approaches that focus on substituting a 
pre-determined variant sequence into the binding loop. This strategy has been successfully used to 
engineer novel inhibitors for furin17, HCV NS3 protease18 and coagulation proteases19 from diverse 
Laskowski inhibitor templates. More recently, synthetic approaches have been developed to identify new 
binding sequences by screening combinatorial20 or non-combinatorial21 libraries of tetrapeptide substrates 
to characterize the non-primed specificity of the target protease. We have previously used this strategy to 
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guide the design of inhibitor variants for several different members of the kallikrein-related peptidase 
(KLK) family, including KLK421, 22 and KLK1423, 24. The success of the substrate-guided approach 
derives from observations that for all Laskowski inhibitors, the non-primed residues of the canonical loop 
interact with the protease to form a β-sheet (spanning from P1 to at least P3) that replicates the binding of 
a conventional substrate (Figure 1A-B)9, 25. As different proteases usually display a unique non-primed 
specificity profile20, modifying the sequence of the inhibitor’s contact β-strand often leads to marked 
changes in its potency and selectivity. Serine proteases also display diversity across their primed binding 
sites that can be targeted in inhibitor engineering studies. Moreover, for Laskowski inhibitors, the primed 
segment is involved in interactions that are specific to the inhibition mechanism, including the religation 
reaction, that are not taken into account when screening substrates. Consequently, there is a need to 
develop new, broadly-applicable strategies for screening the primed residues of the canonical loop to 
increase the coverage of chemistry-based methods for optimizing the binding sequence. 
In this study, we developed a versatile, inhibitor-focused approach for screening preferences at a critical 
residue in the primed segment, P2ʹ. This strategy was based on a novel, broad-range protease inhibitor 
that we recently produced by engineering the fourteen amino acid cyclic peptide, sunflower trypsin 
inhibitor-1 (SFTI-1, Figure 1C-D)24. Using the engineered broad-range inhibitor as a starting point, we 
designed and synthesized a library of twenty P2ʹ variants to screen against diverse serine proteases. The 
library screen revealed unique P2ʹ preferences for thirteen different proteases as well as an overall 
preference for Ile, which is present at P2ʹ in many naturally occurring inhibitors, including SFTI-1. 
Additionally, we used the newly identified P2ʹ preferences to modify known matriptase, KLK14 and 
thrombin inhibitors, generating new variants that displayed improved selectivity. Overall, our study 
presents a versatile cyclic peptide library that makes it possible to rapidly screen P2ʹ preferences for 
diverse serine proteases, and demonstrates that substituting the P2ʹ residue in Laskowski inhibitors, such 
as SFTI-1, is effective for modulating the selectivity of engineered inhibitor variants. 
 
Page 5 of 41 
 
RESULTS 
Design, synthesis and characterization of a P2ʹ diverse inhibitor library. To devise a new screening 
method for optimizing interactions between the primed segment of Laskowski inhibitors and various 
protease targets, we first studied structures of diverse protease/inhibitor complexes. Examining residues in 
the primed segment (P1ʹ-P4ʹ) revealed that interactions formed by the P1ʹ, P3ʹ and P4ʹ residues varied 
between intramolecular and intermolecular interactions across different inhibitor families. However, the 
P2ʹ residue consistently extended out from the inhibitor core and engaged a well-defined pocket (S2ʹ) 
within the protease active site (Figure 1E-F). This suggested that the P2ʹ residue was an ideal target for 
substitution with the aim of changing the inhibitor’s potency and selectivity. Therefore, we set out to 
characterize the P2ʹ specificity of different proteases by designing a synthetic inhibitor library based on 
the naturally occurring cyclic peptide, SFTI-1 (compound 1, Table 1). With only fourteen amino acids, 
SFTI-1 (and engineered SFTI variants) can be readily produced by solid phase peptide synthesis, 
including inhibitors containing non-natural amino acids26, 27. Additionally, SFTI-1 has relatively simple 
architecture, comprising a canonical loop with minimal scaffolding, and thus is an excellent model system 
for examining how various P2ʹ substitutions affect the inhibitor’s activity against different protease 
targets. 
The SFTI variant that we selected for generating the inhibitor library was a broad-range variant (2I, 
compound 2 with Ile at P2ʹ) that we recently engineered24, where residues 2, 12 and 14 of SFTI-1 were 
substituted to re-configure the inhibitor’s intramolecular hydrogen bond network, and P1 Lys was 
replaced with Arg (Figure 2A). These replacements gave rise to an inhibitor that forms minimal side 
chain interactions with the protease’s non-primed binding sites (except for the S1 subsite) as the P2 and 
P4 residues participate in the inhibitor’s hydrogen bond network, and the P3 residue forms a disulfide 
bond with Cys11. As 2I has relatively few selectivity determinants but a prominent hydrogen bond 
network, it effectively inhibits a number of proteases, including trypsin and several members of the 
kallikrein-related peptidase family24. Using 2I as a template, we produced a library of twenty individually 
Comment [A1]: Primed is technically 
correct but sounds a bit discordant. 
Perhaps use “ examining residues on the 
prime side of the scissile bond”? 
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synthesized inhibitors where the P2ʹ residue (Ile7) was substituted (Figure 2B) with each of the naturally 
occurring amino acids (excluding Cys to prevent formation of disulfide bond isomers), or biphenylalanine 
(BiP, single letter code: B) as an example of a non-natural amino acid. 
Peptides were synthesized by standard Fmoc synthesis on acid labile 2-chlorotrityl chloride resin. 
Protected peptides were liberated from the solid support before cyclization in solution using HATU (1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) as the 
activator. After protecting group removal and an initial purification by reverse phase HPLC, disulfide 
bonds were formed before further reverse phase HPLC purification to achieve purities above 95% as 
determined by analytical UPLC (Table 1 and Figure S1, Supporting Information). 
The purified peptides were subsequently characterized by NMR. For SFTI-1 and 2I, we previously 
showed that the inhibitor’s 1D 1H-NMR spectrum exhibits sharp lines and well-dispersed amide 
resonances that are distributed across the 7–9 ppm range with down-field shifted αH signals that are 
indicative of a β-sheet structure24, 28. Similar to that of 2I, the 1D 1H-NMR spectra of the P2ʹ variants 
showed sharp lines and well-dispersed signals (Figure S2, Supporting Information), indicating that they 
were well-folded. In addition, the number of signals (from backbone amides and side chain protons) 
present in the 7–9 ppm region of the spectra suggested that the peptides adopt one main conformation in 
solution. Of all the variants, 2P displayed the greatest conformational flexibility, with the presence of a 
set of additional low intensity signals in its 1D 1H-NMR spectrum that suggest the presence of at least one 
other conformation; this is expected as the replacement of an Ile with the conformationally restricted Pro 
would likely have some effect on the backbone structure. In general though, the NMR data indicate that 
the SFTI-1 variants were well-folded and rigid. 
Exploring the versatility of the inhibitor library against diverse serine proteases. The first proteases 
screened against the P2ʹ inhibitor library were the classical serine proteases, trypsin and chymotrypsin. In 
a previous study, we showed that 2I was a potent inhibitor of trypsin (Ki = 0.7 nM)24, and thus each of the 
twenty inhibitor variants was assayed against trypsin at a low nanomolar range (25 nM). Examining 
Comment [A2]: Folding usually refers 
to tertiary structure – perhaps 
“geometrically stable” would be better 
here? 
Comment [A3]: Lot of use of 
“conformation” here. Maybe replace one 
with “arrangement”  
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trends across the library revealed that substituting the P2ʹ residue led to marked changes in the inhibitor’s 
activity against trypsin (Figure 3). The strongest inhibition was provided by branched hydrophobic 
residues, Ile (80% inhibition) and Val (75%), followed by Arg (65%) and Leu (52%). By contrast, 
variants containing Gly or Pro showed essentially no activity whereas acidic residues, Asp and Glu, also 
generated poor inhibitors. These findings were largely consistent with a previous study that used a 
minimized Bowman-Birk loop peptide (similar to residues 3-11 of the peptides in this study) to examine 
the effect of P2ʹ substitutions on trypsin inhibition29, although the overall level of inhibition in our study 
was several orders of magnitude higher. 
The inhibitor library was also able to provide insight into the P2ʹ specificity of chymotrypsin, even though 
all library peptides contained Arg as the P1 residue which is not favored by chymotrypsin20. While assays 
with chymotrypsin required much higher inhibitor concentrations (25 µM), the data generated was useful 
as the purpose of this screen was to compare the relative activity of each variant at the same 
concentration. Overall, the P2ʹ residues that provided the strongest inhibition were similar to trypsin, 
including hydrophobic residues, Val (76% inhibition) and Ile (60%), and Arg (57%) (Figure 3). However, 
aromatic residues were also strongly preferred, including Trp (63%) and Phe (52%). To explore the 
structural basis for these differences in the P2ʹ specificity profiles for chymotrypsin and trypsin, we used 
molecular dynamics (MD) simulations to examine binding interactions in various protease/inhibitor 
complexes. These analyses revealed that the S2ʹ pocket of chymotrypsin is larger than trypsin, allowing 
bulky P2ʹ residues (Trp) to be accommodated in the space left by Thr151 (Figure S3A), Supporting 
Information). By contrast, trypsin contains Tyr at residue 151, which is able to form cation-π interactions 
with P2ʹ Arg (Figure S3B), Supporting Information), but leaves less space for larger resides, including 
Trp. 
To further test the versatility of the inhibitor library, we screened the catalytic domain of matriptase, a 
type II transmembrane serine protease. Matriptase attracts significant interest as a therapeutic target in 
many epithelial cancers30, and has been the focus of previous inhibitor design studies, including several 
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based on SFTI-126, 27, 31. Across the P2ʹ inhibitor library, three variants out-performed the remaining 
peptides, namely Val (54% inhibition), Ile (41%) and Asn (37%) (Figure 3). Additionally, Asp (29%) 
appeared to be better tolerated by matriptase than seen previously for trypsin and chymotrypsin 
(comparing Asp to the optimal residue for each protease). Examining interactions between matriptase and 
2N (Figure S3C, Supporting Information) indicated that Asn formed favorable interactions within the S2ʹ 
pocket by engaging His143 (His752) – chymotrypsin numbering is used throughout and where relevant, 
specific protease numbering is given in brackets. In 2D, Asp formed similar interactions with His143 
(His752). Collectively, these findings demonstrate that the P2ʹ inhibitor library is effective against diverse 
serine proteases and has the capacity to discern a unique specificity profile for individual enzymes. 
Closely-related proteases from the kallikrein-related peptidase family show distinct P2ʹ 
preferences. Next, we used the P2ʹ inhibitor library to examine specificity divergence among four 
members of the largest known multi-gene serine protease family, the kallikrein-related peptidases 
(KLKs). KLK proteases are involved in a wide range of physiological functions32 and are under 
investigation as therapeutic targets for several indications, including hormone-dependent cancers (prostate 
and ovarian cancers33) and skin diseases34, 35. The non-primed (P1-P4) specificity of several KLKs has 
been studied using combinatorial peptide libraries36, and later by non-combinatorial library screens21, 23 in 
order to guide engineering of the SFTI-1 β-strand. Optimizing the P2ʹ residue provides a further 
opportunity to improve the potency and selectivity of engineered Laskowski inhibitors targeting different 
KLKs. 
Screening the inhibitor library against KLK4, KLK5, KLK7 and KLK14 revealed that each protease had a 
unique P2ʹ specificity profile (Figure 3). KLK4 and KLK14 displayed similar preferences, with the most 
effective variant being Val (92% and 86% inhibition, respectively), followed by Ile, Asn and Arg. 
However, KLK4 also favored aromatic residues (BiP and Phe) but not acidic residues (Glu and Asp), 
whereas the converse was observed for KLK14. Similarly, the most effective inhibitor variant was 
identical for both KLK5 and KLK7 (Asn) which provided 93% and 97% inhibition, respectively. Polar 
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residues were also favored by both proteases, although residues such as His, Gln and Ser provided higher 
inhibition for KLK7 (compared to Val and Ile), but not KLK5. By contrast, the preference for aromatic 
residues (BiP, Tyr, Trp and Phe) appeared more pronounced for KLK5. 
We further investigated the distinct P2ʹ preferences observed for each kallikrein protease by performing 
MD simulations. These analyses revealed that the structural basis for KLK4’s preference for Arg at P2ʹ 
was different to that previously seen for trypsin. Rather than interacting with an aromatic residue, Arg7 
formed a salt bridge with Glu39 in the KLK4 S2ʹ pocket (Figure S4A, Supporting Information). 
Additionally, KLK5’s strong preference for aromatic residues could be explained by T-oriented π 
interactions involving Phe150 (Figure S4B, Supporting Information). For KLK7, the most favored residue 
(Asn) appeared to form a hydrogen bond with the backbone carbonyl of Leu40 (Figure S4C, Supporting 
Information). Finally, the preference for Lys at P2ʹ for KLK14 seemed to involve cation-π interactions 
with Tyr150 (Figure S4D, Supporting Information). These findings illustrate that even closely-related 
proteases (from the same multi-gene family) show differences in their P2ʹ specificity profile that can be 
traced to specific points of sequence diversity in the S2ʹ pocket. 
Profiling the P2ʹ specificity of proteases from the coagulation and fibrinolysis cascade. The 
coagulation and fibrinolysis cascade was among the first proteolytic pathways to be targeted in major 
drug discovery programs2. Dysregulation of this proteolytic cascade is a common theme in many diseases, 
including inflammation, cancer and cardiovascular diseases. Overactive blood coagulation (thrombosis) is 
the most frequent cause of myocardial infarction and stroke37. Additionally, both coagulation and 
fibrinolysis need to be controlled during surgery to reduce bleeding and prevent activation of a systemic 
inflammatory response38. The broad-spectrum Laskowski inhibitor, aprotinin, has been used to inhibit 
proteases that drive both coagulation and fibrinolysis, but it was discontinued in 2008 after 15 years of 
clinical use following a controversial safety trial39. Consequently, there has recently been a renewed effort 
to develop inhibitors that selectively target key serine proteases in the coagulation and fibrinolysis 
pathways. 
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The major direct contributor to coagulation is thrombin, which activates platelets and cleaves fibrinogen 
to generate fibrin40. Screening the P2ʹ inhibitor library against thrombin (Figure 3) revealed a clear 
preference for Tyr (62% inhibition) followed by Asn (49%) and Phe (41%). Molecular modeling 
indicated that the Tyr aromatic ring was accommodated by the wide and flat hydrophobic portion of the 
S2ʹ pocket, while the hydroxyl group formed hydrogen bonds with Arg73 (Arg431) and Asn143 (Asn506) 
(Figure S5B, Supporting Information). The actions of thrombin and the coagulation cascade are countered 
by the fibrinolysis pathway, where plasmin acts to disperse blood clot by degrading fibrin. We have 
previously studied the non-primed (P1-P4) specificity of plasmin using a non-combinatorial peptide 
library41, and screening preferences at P2ʹ using the inhibitor library revealed that Lys (60%) was the most 
favored residue, followed by Ile (50%), Val (25%) and Arg (23%). Molecular modeling suggested that 
P2ʹ Lys can form a salt bridge with Glu143 (Glu685) deep within the plasmin S2ʹ pocket (Figure S5A, 
Supporting Information) while the shallow part of the pocket is hydrophobic, which suits Ile. These 
findings were consistent with a previous study where plasmin’s preference for basic residues at P2ʹ was 
used to engineer a selective plasmin inhibitor based on tissue factor pathway inhibitor-242.  
We were also able to use the P2ʹ inhibitor library to screen proteases in the coagulation cascade that lie 
upstream of thrombin and regulate its activation. Interestingly, factor IXa tolerated both basic and acidic 
residues at P2ʹ, with the strongest inhibition provided by Glu (54%) followed by Arg and Lys (43%). This 
anomaly was resolved by modeling analyses, which revealed that Glu was able to form a salt bridge with 
Arg142 (Arg358) (Figure S5C, Supporting Information), whereas basic residues formed a different salt 
bridge with Asp39 (Asp249). Factor Xa has a narrow S2ʹ pocket and was the only protease that did not 
tolerate Ile (Leu and Trp were also disfavored). Rather, most acidic, aromatic or small residues were 
accepted, including Asp (31%) and Tyr (26%). Molecular modeling suggested P2ʹ Asp formed several 
hydrogen bonds, including a salt bridge with Arg142 (Arg366) (Figure S5D, Supporting Information), 
while Tyr formed a hydrogen bond with Glu39 (Glu257). The inhibitor library also revealed several 
differences in the P2ʹ specificity for factor XIa and factor XIIa. The most preferred P2ʹ residue for factor 
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XIa was Val (65%), followed by Ile (47%) and Asp (34%), whereas factor XIIa favored aromatic and 
branched hydrophobic residues, with the strongest inhibition provided by Trp (87%), closely followed by 
Ile (85%), Val (80%), BiP (80%) and Tyr (75%). Factor XIa has a narrow and hydrophobic S2ʹ pocket, 
which ideally fits Val (Figure S5E, Supporting Information), while Arg39 (Arg413) located at the far end 
of the pocket enables hydrogen bonding with acidic residues. By contrast, factor XIIa has a much larger 
S2ʹ pocket with Tyr150 (Tyr377) at its base, allowing for aromatic ring interactions with Trp (Figure S5F, 
Supporting Information) or Tyr. 
Exploiting P2ʹ specificity differences to engineer new inhibitor variants that show improved 
selectivity. Previous studies have used SFTI-1 to design new inhibitors for a diverse array of protease 
targets21, 24, 26, 27, 31, 43, 44. These engineered variants were developed using a range of different strategies, 
but in several cases, the P2ʹ residue (Ile) was not targeted for refinement. Therefore, to explore whether 
the P2ʹ specificity data from our study can be used in the design process to improve the selectivity of 
engineered inhibitors, we studied the effect of substituting Ile7 in existing SFTI variants that were 
developed to inhibit matriptase, KLK14 and thrombin. 
As with members of the inhibitor library, we acquired 1D 1H-NMR spectra to confirm that the new 
engineered inhibitors (Table 1) had folded correctly. As shown in Figure S2 (Supporting Information), the 
spectra showed sharp lines and well-dispersed signals, indicating that the engineered inhibitors were well-
folded. The intensity and number of amide resonances in the spectra suggests that most of the inhibitors 
adopt one main conformation in solution, with the exception of 4, which adopts multiple conformations. 
To investigate this further, we acquired 2D homonuclear TOCSY and NOESY spectra of 4. Based on the 
presence of NOEs between the Hα/Hδ of a Pro and the Hα of the preceding residue, we found that the 
conformational heterogeneity was due to cis-trans isomerization of the Asp7-Pro8 and Pro8-Pro9 peptide 
bonds. 
Matriptase. To date, the most common target in SFTI-based engineering studies has been the cancer-
related protease, matriptase26, 27, 31. In one study, a high affinity SFTI variant for matriptase was developed 
Page 12 of 41 
 
using a truncated inhibitor scaffold (spanning residues 1-12) with a non-cyclic peptide backbone and an 
amidated C-terminus27 (Compound 3, Table 2). However, an ongoing challenge in designing SFTI-based 
inhibitors for matriptase has been achieving a suitable degree of selectivity. Indeed, 3 was reported to 
show only 6-fold selectivity for matriptase over trypsin27. Our inhibitor library screen indicated that 
matriptase and trypsin had divergent P2ʹ specificity profiles (Figure 3). In particular, matriptase seemed to 
tolerate Asp at P2ʹ reasonably well (compared to Ile), whereas Asp was poorly favored by trypsin. With 
the aim of improving the selectivity of 3 for matriptase over trypsin, we synthesized 3 and the 
corresponding Asp7 variant, 4. Screening both compounds against matriptase revealed that Asp7 was 
tolerated almost as well as Ile7 with only a slight decrease in activity observed for 4 (Table 2). Modeling 
4 in complex with matriptase indicated that Asp7 formed a favorable hydrogen bond with His143 
(His752) (Figure 4A), that was similar to that seen for P2ʹ Asn. However, equivalent assays with trypsin 
revealed that the Asp7 variant showed a 350-fold decrease in activity compared to 3 (P2ʹ Ile), which 
improved the inhibitor’s selectivity to 33-fold (under the assay conditions in our study, we found that 3 
was a more potent inhibitor of trypsin than matriptase). Further, 4 showed 196-fold selectivity over 
plasmin due to lower off-target activity compared to 3, while neither variant 3 nor 4 showed any 
inhibition of thrombin up to 50 µM (Table 2). 
KLK14. A further therapeutic application where SFTI variants are currently under development is for 
inhibiting kallikrein proteases implicated in skin diseases24, 45. In a recent study, we designed a potent and 
selective inhibitor for KLK14 (5, Table 1) by engineering the SFTI-1 contact β-strand (P4-P1 residues) as 
well as residues 12 and 1424. This variant is a potent KLK14 inhibitor (Ki = 2.0 nM) and shows 
approximately 180-fold selectivity over KLK5 and trypsin. Our data from the P2ʹ library screen indicated 
that Lys7 was reasonably well tolerated by KLK14, but was strongly disfavored by related skin proteases, 
KLK5 and KLK7 (Figure 3). This suggested that replacing Ile7 with Lys could further increase the 
selectivity of 5. The P2ʹ Lys variant (6) showed a slight decrease in activity against KLK14 (Ki = 7.0 nM, 
Table 2), but had dramatically lower activity against KLK5 and KLK7 (Ki > 50,000 nM), which 
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represents more than 7,000-fold selectivity over these proteases. Molecular modeling of 6 in complex 
with KLK14 indicated that Lys7 was involved in cation-π interactions with Tyr150 (Tyr158) (Figure 4B) 
as seen with 2K in the initial library screen. Additionally, 6 showed 8.4-fold weaker inhibition of trypsin 
compared to 5 (457-fold selectivity), but maintained reasonable activity against KLK4 (Table 2), which 
was consistent with data from the inhibitor library screen (Figure 3). 
Broad-range kallikrein inhibitors. In addition to engineering selective inhibitors for skin kallikrein 
proteases, there is growing interest in developing multi-target inhibitors where a single variant shows 
potent activity against KLK5, KLK7 and KLK1446. We found that the starting compound in the P2ʹ 
inhibitor library (2I) was a potent inhibitor of all three kallikrein proteases (Table 2). A further 
consideration is whether the multi-target inhibitor should also block matriptase as this protease has been 
implicated in activating KLK5 and KLK7 in skin diseases47. However, deficient matriptase activity is also 
implicated in causing a skin disease (ichthyosis hypotrichosis syndrome)48 and thus, a broad-range 
inhibitor showing activity against matriptase may carry a risk of negative side-effects. In assays with 
matriptase, 2I showed weak activity (Ki = 15,700 nM), corresponding to at least 930-fold selectivity for 
KLK5, KLK7 and KLK14. Yet, when the remaining P2ʹ variants in the library screen were considered, it 
appeared that replacing Ile7 with Asn (2N) could provide a more effective KLK5, KLK7 and KLK14 
inhibitor without compromising the variant’s low activity against matriptase. Whereas 2N showed a slight 
decrease in activity against KLK5 and KLK14 compared to 2I, inhibition of KLK7 was improved by over 
20-fold (Table 2). Additionally, 2N showed weaker activity against matriptase (Ki = 37,300 nM), which 
equates to over 7,000-fold selectivity. 
Thrombin. Activation of thrombin is a key step in the coagulation pathway, and thus a considerable 
amount of research has focused on the development of potent and selective thrombin inhibitors40. 
Although SFTI-1 is a poor inhibitor of thrombin (Ki = 5,000 nM), a previous study showed that 
substituting the P1 Lys residue with Arg (7) could improve the inhibitor’s activity by almost 6-fold (Ki = 
860 nM)26. Our findings from the P2ʹ inhibitor library revealed that Tyr7 (62%) led to stronger inhibition 
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of thrombin than Ile7 (39%). Additionally, Tyr7 appeared to be less favored by plasmin and matriptase 
compared to Ile. Screening 7 and the corresponding P2ʹ Tyr variant (8) against thrombin revealed that 
replacing Ile7 with Tyr led to a further increase in activity (Table 2). Modeling 8 in complex with 
thrombin revealed similar interactions involving P2ʹ Tyr (Figure 4C) as seen previously with 2Y. Further, 
comparing inhibition of other proteases by 7 and 8 revealed that 8 showed 5-fold lower activity against 
trypsin and plasmin, and more than 90-fold lower activity against matriptase. While 8 remains a very 
potent trypsin inhibitor and may have limited potential for therapeutic development, these proof-of-
concept findings indicate that P2ʹ Tyr can be incorporated into a future SFTI-based inhibitor for thrombin 
to improve its potency and selectivity. 
 
DISCUSSION AND CONCLUSIONS 
In this study, we developed a new library of cyclic peptide inhibitors that can be used to characterize the 
P2ʹ specificity of different serine proteases in order to improve the selectivity of engineered inhibitor 
variants. Screening the inhibitor library against thirteen different proteases revealed several common 
preferences but ultimately, a unique P2ʹ specificity profile was identified for each enzyme. These effects 
were explored further using MD simulations where we found that the distinct P2ʹ preferences for each 
protease were often linked to regions of sequence diversity in the S2ʹ binding pocket. Finally, we used the 
newly identified P2ʹ specificity profiles to further optimize existing engineered inhibitors based on SFTI-
1, demonstrating that our data from the inhibitor library screen is transferrable to other SFTI variants. 
Together with existing substrate-guided approaches, the strategy described in this study now makes it 
possible to use synthetic chemistry-based methods to screen key residues on both the primed and non-
primed sides of the inhibitor’s binding loop, allowing engineered variants to achieve higher potency and 
selectivity. 
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This study has first demonstrated that the P2ʹ residue has considerable potential for modulating the 
potency and selectivity of engineered Laskowski inhibitors. In existing structures of serine proteases, the 
S2ʹ pocket is typically well-defined and has a unique configuration in different proteases due to variation 
in sequence or loop conformation, hinting that interactions involving the P2ʹ residue are important to the 
enzyme’s binding specificity. Additionally, studies on mesotrypsin have shown that interactions involving 
the S2ʹ subsite and P2ʹ residue have a major role in the protease’s notorious resistance to Laskowski 
inhibitors (including aprotinin)49, 50. However, until now, there has been a lack of systematic, broadly-
applicable methods for screening the P2ʹ specificity profile of target proteases (in the context of protease 
inhibition) to identify suitable modifications that can be harnessed in engineering studies. Using our 
library of P2ʹ inhibitor variants, we found that a range of residues with different biophysical properties 
were favored by various proteases, to the extent that almost all of twenty P2ʹ residues included in the 
study were highly preferred by at least one of the thirteen enzymes screened (Figure 3). Moreover, using 
these data to guide substitution of the P2ʹ residue in a series of existing engineered inhibitors (for 
matriptase, KLK14 and thrombin) yielded new variants that showed marked improvements in selectivity. 
Interestingly, the P2ʹ substitutions were found to be effective regardless of whether the initial library 
screen was performed at low (25 nM) or high concentration (10-25 µM), further demonstrating the 
versatility of the method. Additionally, the slight decrease in potency for the new KLK14 and matripase 
variants was fully consistent with data from the library screen, as Ile (present in the starting variant) was 
more favored than new residue (Lys and Asp, respectively) and the substitution was made with the 
intention of improving the inhibitor’s selectivity. 
The findings presented here also provide new insights into the significance of Ile at P2ʹ in SFTI-1 and its 
prevalence in structurally-related inhibitors from the Bowman-Birk family. SFTI-1 has been found to 
inhibit a number of proteases with reasonably high affinity, including trypsin, matriptase, cathepsin G, 
KLK4, KLK5, KLK1421, 24, 26, 51. Across all P2ʹ residues included in the inhibitor library, we found that Ile 
was one of the most preferred residues for almost all proteases screened (Figure 3), together with Val, 
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which is structurally similar to Ile. Additionally, Ile is found at P2ʹ in almost half of the 190 Bowman-
Birk inhibitor sequences (from different species) listed in the MEROPS database52 (Figure 5A). In an 
earlier study, Leatherbarrow and colleagues suggested that Ile may be prevalent at P2ʹ in Bowman-Birk 
inhibitors either to favor broad-range inhibition or to allow the binding loop to adopt an optimal 
conformation for interaction with the protease29. Our findings across thirteen diverse serine proteases 
provide new evidence that supports the former hypothesis (broad-range inhibition). Indeed, Ile appeared 
to be dispensable at P2ʹ as although it was favored by most proteases, we identified chemically diverse 
P2ʹ residues that performed as well or better than Ile for each protease screened, suggesting that Ile is not 
a structural requirement for Bowman-Birk inhibitors. Interestingly, branched hydrophobic residues (Val, 
Ile and Leu) are also found at P2ʹ in over 80% of serine protease pro-segments that undergo cleavage 
during zymogen activation (Figure 5B). This suggests that broad-range Laskowski inhibitors and their 
protease targets have both capitalized on the widespread preference for branched hydrophobic residues at 
P2ʹ for the purpose of generating binding motifs that are tolerated by many different serine proteases. By 
extension, the broad tolerance of Ile and Val at P2ʹ is also significant in the context of inhibitor 
engineering, as retaining these types of residues at P2ʹ is likely to limit the selectivity of new inhibitor 
variants. 
Considering the broader aspects of the Laskowski mechanism and serine protease catalysis, the primed 
segment of the binding loop has an especially important role in the inhibitor’s activity, as seen in this 
study. During serine protease catalytic processing, once the scissile bond has been cleaved, the primed 
segment becomes the initial leaving group, whereas the non-primed segment remains covalently bound to 
the protease via an ester bond (acyl-enzyme complex)53. For Laskowski inhibitors, the positioning of the 
neo-N-terminus (P1ʹ residue) appears to be critical for efficient religation as it is proposed to engage the 
catalytic His residue (in place of the hydrolytic water molecule) to initiate the resynthesis reaction54, 55. 
Therefore, the degree of complementarity between the primed segment of the inhibitor and the protease 
will probably have a strong influence on whether cleavage of the reactive site bond leads to hydrolysis or 
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religation (as seen previously with mesotrypsin49, 50). Since these interactions are specific to the inhibitory 
mechanism, it may not be as effective to use substrate-based screens to identify primed segment 
substitutions as the set of sequences that are cleaved rapidly will also include those that generate efficient 
leaving groups. Indeed, although existing P2ʹ cleavage specificity data for trypsin, thrombin and factor 
Xa56 shows a number of similarities with our inhibitor library data, the overall level of correlation is only 
modest. However, by using a substrate-guided approach to optimize the non-primed residues, followed by 
an inhibitor-based screen to refine the primed segment, we were able to overcome this problem and 
developed a potent KLK14 inhibitor, for example, that showed more than 7,000-fold selectivity over 
closely-related skin proteases, KLK5 and KLK7. 
The potency and selectivity of the new inhibitor variants described in this study compare favorably with 
those developed by existing methods, including phage display. While phage display has major advantages 
relating to the number of variants that can be screened, its ability to scan both primed and non-primed 
residues simultaneously, and it is entirely inhibitor-based, our synthetic chemistry approach is versatile, 
allows validation that each library member is present (in the same concentration), and focuses solely on 
variants that bind within the active site. Thus, selection of variants that are not effective inhibitors of the 
target protease, as seen in a previous phage display study involving thrombin15, is avoided. However, 
there are several factors that should be considered when transferring this study’s findings to other 
engineered inhibitors. First, all variants in the inhibitor library contain Arg as the P1 residue. Therefore, 
we cannot exclude the possibility that certain residues may become more or less favored (due to co-
operativity effects) when the P1 (or an adjacent) residue is changed. For example, in an engineered 
variant containing Phe at P1, we have noticed that P2ʹ Tyr becomes highly favored by chymotrypsin. 
Second, although the geometry of the binding loop is conserved across all Laskowski inhibitors, how well 
the specificity trends identified in this study transfer to scaffolds from other inhibitor families remains to 
be investigated. Here, it is important to note that in SFTI-1 (and many other Bowman-Birk inhibitors), the 
primed segment has a unique conformation as the P2ʹ residue is followed immediately by two Pro 
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residues (or in some cases, one Pro and a small residue). Thus, the inhibitor backbone bends away 
(forming an anti-parallel β-strand with the P4-P1 residues) without engaging the conventional S3ʹ or S4ʹ 
binding sites. 
In conclusion, our study demonstrates that the P2ʹ residue has a strong influence on Laskowski inhibitor 
potency and selectivity, and unveils a novel, inhibitor-based library screen to guide optimization of the 
P2ʹ residue in future engineering studies. We anticipate that the P2ʹ specificity profiles determined in this 
study will help to improve the potency and/or selectivity of engineered SFTI variants targeting many of 
the proteases we screened, many of which have pharmaceutical indications. Additionally, the inhibitor 
library is itself a valuable resource that, once synthesized and validated, can be screened against further 
proteases under investigation as targets for inhibitor design. Indeed, this strategy contributes to making 
more of the canonical loop accessible to optimization by synthetic chemistry-based methods, and when 
combined with a systematic approach for refining the non-primed binding sequence, provides a promising 
blueprint for engineering potent and selective serine protease inhibitors. 
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EXPERIMENTAL SECTION 
Protein Expression and Protein Sources 
Recombinant KLK proteases used in this study were expressed in zymogen (pro) form in Pichia pastoris 
strain X-33 (KLK5 and KLK7) or Spodoptera frugiperda Sf9 insect cells (KLK4 and KLK14), then 
purified and activated as described recently24. Active site titration was performed using either α2-
antiplasmin (Sino Biological) (KLK5), α1-antitrypsin (Sigma-Aldrich) (KLK7) or 4-methylumbelliferyl-
p-guanidinobenzoate (MUGB, Sigma-Aldrich) (KLK4 and KLK14). Active KLKs were supplemented 
with 20% (v/v) glycerol to allow storage at ‒80°C with minimal losses of activity. Remaining proteases 
were obtained from commercial distributers: β-trypsin, α-chymotrypsin, plasmin and factor XIa (Sigma-
Aldrich); matriptase (R&D Systems); α-thrombin, factor IXa-β, factor Xa and factor α-XIIa (Molecular 
Innovation). 
Peptide Synthesis  
Cyclic inhibitors (including the P2ʹ inhibitor library and protease-targeted variants) were synthesized on 
2-chlorotrityl chloride resin (0.8 mmol/g) while linear inhibitors were synthesized on Rink amide MBHA 
resin (0.8 mmol/g) using a Symphony automated peptide synthesizer (Protein Technologies, Inc). For 
coupling reactions, Fmoc N-protected amino acids (4 equiv) were activated with 4 equiv O-(6-
chlorobenzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU) and 8 equiv N,N-
diisopropylethylamine (DIPEA) in DMF (2 × 5 min reactions per residue). The Fmoc protecting group 
was subsequently removed using 30% piperidine in DMF (2 × 3 min). Assembled peptides (retaining 
side-chain protecting groups) were cleaved from the resin using 1% TFA in DCM, and collected by 
precipitation in diethyl ether. Head-to-tail cyclization was performed in DMF (50 mL per 0.1 mmol 
peptide) with 4 equiv 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU) and 8 equiv DIPEA at room temperature for 3 hours. To remove DMF and 
activators, the post-cyclization solution was mixed with an equal volume of DCM, and then washed with 
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5 volumes of H2O (2-3 times). The organic phase was recovered, solvent was removed by rotary 
evaporation, and side-chain protecting groups were removed by cleavage using 
TFA/triisopropylsilane/H2O (96:2:2) (20 mL per 0.1 mmol peptide). Fully deprotected peptides were 
collected by precipitation in diethyl ether. Formation of the intramolecular disulfide bond was achieved 
by vigorous stirring at room temperature (3 hours) in 0.1 M sodium bicarbonate buffer (pH 8.5) 
containing 10 µM oxidized glutathione (total volume: 100 mL per 0.1 mmol peptide). 
Peptide para-nitroanilide (pNA) substrates were synthesized using 2-chlorotrityl chloride resin that had 
been derivatized with para-phenylenediamine (Sigma Aldrich), as previously described57. Assembly of 
linear peptides and liberation of protected peptides from the solid support was performed as above. 
Oxidation of the C-terminal para-aminoanilide group was carried out in solution using 6 equiv Oxone 
(Sigma Aldrich), as previously described57. Side-chain protecting groups were removed by TFA cleavage 
as described for SFTI variants. 
Peptide Purification and Mass Spectrometry Analysis 
SFTI variants and peptide-pNA substrates were purified by reverse phase  HPLC (Shimadzu Prominence) 
using a 5 µm ZORBAX Extend-C18 PrepHT column (21.2 × 250 mm) and a linear gradient of 10% 
acetonitrile/0.05% TFA to 50% acetonitrile/0.05% TFA. Peptide purity (> 95%) was confirmed by UPLC 
using a 5 µm Agilent 300 SB C18 column (2.1 × 50 mm) at 50°C with mobile phases as above (Figure 
S1, Supporting Information). Peptide masses were determined by electrospray ionization mass 
spectroscopy (Shimadzu Prominence, Table 1). 
1D NMR 
Unless otherwise stated, peptide TFA salts were dissolved in H2O:D2O (9:1) at a concentration of 1.2 mM 
(pH 3-4) including 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) as an internal standard (2 µg/mL, 
referenced at 0.00 ppm). 1H NMR spectra were collected on a Bruker Avance-600 MHz spectrometer at 
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298 K. For TOCSY and NOESY experiments, a mixing time of 80 ms and 200 ms was used, respectively. 
Spectra were processed with TOPSPIN 2.1 and further analyzed with CCPNMR 2.2.2 if required. 
Inhibition Assays  
Inhibition assays were performed in 96-well low-binding plates using 250 µL assay buffer (0.1 M Tris pH 
8.0, 0.1 M NaCl and 0.005% Triton X-100) and 100 µM peptide-pNA substrates. Enzyme concentrations, 
protease-specific buffer additives and substrates are listed in Table S1 (Supporting Information). 
Proteolytic activity was measured by monitoring release of the pNA moiety using a plate reader 
spectrophotometer (λ = 405 nm, reading interval: 10 s, assay time course: 300 s), and the level of 
inhibition was calculated by comparing kinetic rates to control assays without inhibitor. Substrate 
constants (Michaelis–Menten) and inhibition constants (Morrison Ki) were determined by non-linear 
regression using GraphPad Prism 6.0. 
Molecular Modeling 
For proteases where their structure in complex with SFTI-1 has not been determined by x-ray 
crystallography, protease/SFTI complexes were generated by overlay of the trypsin/SFTI-1 complex 
(PDB ID: 1SFI) with existing structures for each protease: chymotrypsin (PDB ID: 1CHO), KLK5 (PDB 
ID: 2PSX), KLK7 (PDB ID: 2QXI), plasmin (PDB ID: 3UIR), thrombin (PDB ID: 3VXE), factor IXa 
(PDB ID: 3LC3), factor Xa (PDB ID: 2JKH), factor XIa (PDB ID: 3SOR). Additionally, homology 
models were created for KLK14 and factor XIIa using SWISS-MODEL58 and the templates KLK5 (PDB 
ID: 2PSX) and hepatocyte growth factor activator (PDB ID: 2R0L), respectively. For KLK4 and 
matriptase, existing protease/SFTI complexes were used (PDB ID: 4KEL and 3PF8). Systems were 
solvated with TIP3P water and neutralized by Na+/Cl- counter ions to a final concentration of 100 mM in 
VMD 1.9.159. This generated systems of approximately 22,000-25,000 atoms including 6,000-7,000 water 
molecules. 
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Each protease/inhibitor complex was equilibrated using a stepwise relaxation procedure. First, all heavy 
atoms were harmonically restrained with a force constant of 2 kcal/(mol Å2) before a conjugate gradient 
minimization was performed (500 steps) using NAMD 2.960 and CHARMM27 force fields parameters. 
This was followed by heating to 298 K and simulating 500 ps under NPT conditions with periodic 
boundary conditions. A Langevin thermostat with a damping coefficient of 0.5 ps-1 was used to maintain 
the system temperature and the system pressure was maintained at 1 atm using a Langevin piston barostat. 
The particle mesh Ewald algorithm was used to compute long-range electrostatic interactions at every 
time step and non-bonded interactions were truncated smoothly between 10-12 Å. Hydrogen bonds were 
constrained by the SHAKE algorithm (or the SETTLE algorithm for water). For the second stage, the 
restraints were retained on the protease and inhibitor α-carbons only (1 ns), while all constraints were 
released in the third stage (1 ns). Production runs (10 ns) were performed under NVT conditions with 
otherwise identical force field and simulation parameters as above. Coordinates were saved every 100 
simulation steps producing 50,000 frames per trajectory. 
Sequence Alignments 
The Bowman-Birk inhibitor (family I12) sequence alignment was performed using all 190 sequences 
listed in the MEROPS database v9.1252 (date accessed: 9 April 2015). For the human serine protease 
alignment, all sequences (139) were extracted from the UniProt proteome database 
(http://www.uniprot.org/proteomes/) (date accessed: 9 April 2015). Sequences were aligned using Clustal 
Omega 1.261, with only serine protease sequences found to contain a canonical pro-sequence included in 
the alignment (112 out of 139). Graphics illustrating sequence diversity were generated using WebLogo 
3.4 (http://weblogo.threeplusone.com/). The structure-based sequence alignment of 13 serine proteases in 
Figure S6 (Supporting Information) was generated using Chimera 1.8.1 and the PDB structures described 
above. 
Supporting Information Available: Contains compound characterization (analytical UPLC traces and 
1D NMR spectra), molecular modeling, structure-based protease sequence alignment, and protease-
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specific kinetic assay conditions. This material is available free of charge via the Internet at 
http://pubs.acs.org. 
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FIGURES  
Figure 1 
 
 
Figure 1: Structural features of the serine protease active site and binding interactions with 
sunflower trypsin inhibitor-1 (SFTI-1). (A) Schematic diagram showing binding of a Laskowski 
inhibitor (via the canonical loop) (green) to a serine protease (black) illustrating the substrate binding sites 
(S4-S4ʹ) and protease binding residues (P4-P4ʹ). (B) Schematic diagram showing binding of a 
colorimetric tetrapeptide substrate (blue) to a serine protease (black) with interactions between the P4-P1 
residues and the S4-S1 sites. The colorimetric reporter group is represented as a symbol (near the S1ʹ 
pocket). (C) Schematic drawing of the SFTI-1 sequence. Cysteine residues forming the disulfide bond are 
highlighted in yellow and the protease binding residues (P4-P4ʹ) are labeled (grey text). Inside the 
schematic is a ribbon diagram of the solution structure of SFTI-1 (green, PDB ID: 1JBL) with the 
disulfide bond shown in stick representation (yellow). (D) Ribbon diagram of SFTI-1 (green) in complex 
with trypsin (grey, PDB ID: 1SFI). The catalytic triad of trypsin (His57, Asp102 and Ser195) and the 
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disulfide bond of SFTI-1 are shown in stick representation. (E) Molecular surface of trypsin (grey) 
illustrating the SFTI-1 binding sites S4-S2ʹ (green). (F) Structure of SFTI-1 (stick representation) bound 
to trypsin (molecular surface colored by electrostatic potential) highlighting the S1 and S2ʹ substrate 
binding sites. 
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Figure 2 
 
Figure 2: Designing a cyclic inhibitor library for screening the P2ʹ specificity of diverse serine 
proteases. (A) The structure of the starting compound 2I was determined by NMR spectroscopy (BMRB 
accession code: 21057)24 and is shown in stick representation. The variable P2ʹ residue is colored orange, 
the disulfide bond shown in yellow, intramolecular hydrogen bonds are represented by dashed lines 
(purple), and remaining atoms are colored as follows: carbon (green), oxygen (red), nitrogen (blue). (B) 
The sequence of the template for the SFTI library based on compound 2I showing the atom backbone of 
the residue 7 and the variable side chain as -R. 
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Figure 3 
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Figure 3: Inhibitory activity of a SFTI-based library with a variable P2ʹ residue against thirteen 
serine proteases. The variable residue at the P2ʹ position is shown on the x-axis using single letter code 
for naturally occurring amino acids (B denotes biphenylalanine). The % inhibition (y-axis) for each 
variant was calculated by comparing kinetic rates to control assays without inhibitor. Data is expressed as 
mean ± S.E.M. from three independent experiments performed in duplicate. For each protease, the 
concentration of peptide used to screen the inhibitor library is given in brackets after the protease name. 
In the bottom row, the average P2ʹ preference (middle panel) was generated by normalizing the level of 
inhibition for each residue to Ile7 (set as 100%), and then calculating the mean for each residue across all 
proteases (excluding FXa since data could not be normalized as the P2ʹ Ile variant showed almost no 
inhibition).  
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Figure 4 
 
 
Figure 4: Molecular dynamics simulations reveal new favorable interactions introduced by library-
guided P2ʹ substitutions. Average simulation structures for (A) matriptase/compound 4, (B) 
KLK14/compound 6, and (C) thrombin/compound 8 were calculated from 10 ns simulation trajectories 
(see methods for full details). Proteases are illustrated as ribbon diagrams (grey, left panels) or molecular 
surface graphics (colored by electrostatic potential, right panels) and inhibitors are shown in stick 
representation in both panels. Atom colors used are: carbon (green), nitrogen (blue), oxygen (red) and 
sulfur (yellow). Hydrogen bonds are represented by purple dashed lines. 
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Figure 5 
 
 
 
Figure 5: Sequence diversity in the canonical loop of Bowman-Birk inhibitors and at the P2ʹ residue 
in the pro-segment of human serine protease zymogens. (A) Sequence diversity across the P4-P4ʹ sites 
in all Bowman-Birk inhibitors (family I12) currently listed in the MEROPS database52. (B) Sequence 
diversity at the P2ʹ residue in the pro-segment of all human serine protease zymogens that have a 
canonical pro-region. 
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TABLES 
Table 1: Sequences, masses and purity of SFTI inhibitor variants 
Compound Peptide sequencea,b Theoretical mass Determined mass Purity (%) 
1 GRCTKSIPPICFPD - - - 
2A GTCTRSAPPICNPN 1410.6 1410.3 99.2 
2D GTCTRSDPPICNPN 1454.6 1454.2 96.2 
2E GTCTRSEPPICNPN 1468.6 1468.2 99.0 
2F GTCTRSFPPICNPN 1486.7 1486.4 98.8 
2G GTCTRSGPPICNPN 1396.6 1396.2 98.6 
2H GTCTRSHPPICNPN 1476.7 1476.5 99.2 
2I GTCTRSIPPICNPN 1452.7 1452.4 99.9 
2K GTCTRSKPPICNPN 1467.7 1467.6 98.3 
2L GTCTRSLPPICNPN 1452.7 1452.4 98.5 
2M GTCTRSMPPICNPN 1470.7 1470.4 99.8 
2N GTCTRSNPPICNPN 1453.6 1453.5 97.3 
2P GTCTRSPPPICNPN 1436.6 1436.4 98.1 
2Q GTCTRSQPPICNPN 1467.7 1467.9 99.6 
2R GTCTRSRPPICNPN 1495.7 1495.9 98.9 
2S GTCTRSSPPICNPN 1426.6 1426.4 99.9 
2T GTCTRSTPPICNPN 1440.6 1440.6 99.3 
2V GTCTRSVPPICNPN 1438.7 1438.4 99.1 
2W GTCTRSWPPICNPN 1525.7 1525.5 96.2 
2Y GTCTRSYPPICNPN 1502.7 1502.4 97.7 
2B GTCTRSBPPICNPNc 1562.7 1562.4 99.9 
3 GRCTKSIPPRCH-NH2 1351.6 1351.4 96.4 
4 GRCTKSDPPRCH-NH2 1353.5 1353.3 99.9 
5 GWCIRSIPPICNPN reported in ref. 24                        - - 
6 GWCIRSKPPICNPN 1564.9 1564.6 97.8 
7 GRCTRSIPPICFPD 1541.8 1541.5 99.9 
8 GRCTRSYPPICFPD 1591.8 1591.5 99.9 
aResidues that are mutated from compound 2I are shown in bold for compounds 2A-2Y (the P2ʹ residue is 
underlined). All peptides excluding compounds 3 and 4 have a cyclic backbone.  
bResidues that are mutated from SFTI-1 (1) are displayed in bold for compounds 3-8 
cB: Biphenylalanine (BiP) 
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Table 2. Inhibition constants for engineered SFTI variants with P2ʹ substitutions 
Compound Sequencea Ki (nM) 
  Matriptase Trypsin Plasmin Thrombin 
3 GRCTKSIPPRCH-NH2 81.9 ± 6.8 8.0 ± 0.9 14,300 ± 1,400 > 50,000 
4 GRCTKSDPPRCH-NH2 87.0 ± 9.1 2,830 ± 111 17,100 ± 2,200 > 50,000 
  KLK14 KLK5 KLK4 Trypsin 
5 GWCIRSIPPICNPN 2.0 ± 0.1 362 ± 14 9.0 ± 0.9 379 ± 9.2 
6 GWCIRSKPPICNPN 7.0 ± 0.5 > 50,000 19.9 ± 0.6 3,200 ± 99 
  KLK5 KLK7 KLK14 Matriptase 
2I GTCTRSIPPICNPN 2.1 ± 0.1 16.8 ± 0.4 0.4 ± 0.02 15,700 ± 2,200 
2N GTCTRSNPPICNPN 5.2 ± 0.2 0.8 ± 0.05 1.2 ± 0.07 37,300 ± 7,500  
  Thrombin Trypsin Matriptase Plasmin 
7 GRCTRSIPPICFPD 381 ± 13 0.03 ± 0.002 546 ± 21 121 ± 7.0 
8 GRCTRSYPPICFPD 214 ± 13 0.16 ± 0.007 > 50,000 549 ± 31 
aResidues that are mutated from SFTI-1 (1) are displayed in bold font and the P2ʹ residue is underlined 
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